Why Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Fell 12.4% on Sep 15, 2026
The clearest new catalyst: First-in-human ARO-DIMER-PA data (Phase 1/2a, single-dose interim).
Why did ARWR stock fall?
Arrowhead Pharmaceuticals fell 12.40% to $70.67 on Tuesday, September 15, 2026 — its worst day in over a year — even though its first-in-human data for ARO-DIMER-PA, released before the open, were positive. The Phase 1/2a single-dose interim results showed deep lipid reductions with no drug-related serious adverse events, but the stock had run hard into the readout and the disclosure was single-dose only, so the sharp drop read as sell-the-news/profit-taking rather than a reaction to disappointing data.
- First-in-human ARO-DIMER-PA data (Phase 1/2a, single-dose interim): Before the open on September 15, Arrowhead reported the first clinical readout of ARO-DIMER-PA, its first dual-functional RNAi 'dimer' — one molecule designed to silence both PCSK9 and APOC3 in liver cells to lower LDL cholesterol and triglyceride-rich lipoproteins in patients with mixed hyperlipidemia/ASCVD risk. The interim single-dose results were strong: PCSK9 down 72%, APOC3 down 88%, LDL-C down 54%, triglycerides down 73%, non-HDL cholesterol down 61% and ApoB down 50%, with no drug-related serious adverse events (injection-site reactions and headaches most common); the multiple-dose portion is ongoing.
- A sell-the-news reaction, not disappointing data: Contemporary coverage described the early data as positive, so the drop is best read as a sell-the-news/profit-taking move: the shares had run strongly into the catalyst, expectations were high, and the topline disclosure was limited to single-dose data, with fuller details reserved for a future medical meeting. It was not a case of the data being objectively poor.
- Worst single day in over a year: Selling intensified into the close — an intraday snapshot had the stock down about 8.9% at $73.47 before it finished down 12.40% at $70.67 — making it Arrowhead's worst single session in more than a year. The move came on a down day for the broad market (S&P 500 -0.45%, Nasdaq -0.78%).
How the story developed
- September 15, 2026 (pre-market)Arrowhead reports positive first-in-human ARO-DIMER-PA Phase 1/2a single-dose interim data (deep PCSK9/APOC3/LDL/triglyceride reductions, no drug-related SAEs).
- September 15, 2026ARWR sells off into the close, finishing down 12.40% at $70.67 — its worst day in over a year — in a sell-the-news reaction.
What it could mean for ARWR investors
The constructive case
- The single-dose data were strong across every lipid measure with a clean early safety profile, validating the dual PCSK9/APOC3 'dimer' concept.
- A stock that sold off on positive news can re-rate as the multiple-dose and fuller datasets arrive.
The cautious case & what could invalidate it
- Expectations were clearly high; the sell-off shows how much good news was already priced in.
- The disclosure was single-dose only, with fuller data reserved for later — so the readout was incomplete.
- As an early-stage (Phase 1/2a) asset, ARO-DIMER-PA still faces a long path through the multiple-dose and later trials.
Initial detection
BestStocks first flagged ARWR intraday on Sep 15, 2026; this analysis was finalized after the close using the confirmed −12.4% session move and additional catalyst research.
Show the initial intraday note
Arrowhead Pharmaceuticals, Inc. (ARWR) fell 12.40% to close at $70.67 on Tuesday, September 15, 2026 — its worst day in over a year — despite reporting positive first-in-human data for ARO-DIMER-PA before the open. The Phase 1/2a single-dose interim results were strong (deep reductions in PCSK9, APOC3, LDL cholesterol and triglycerides), but the stock had run up sharply into the readout and the disclosure was limited to single-dose data, so the reaction looked like a classic sell-the-news / profit-taking move rather than a response to weak data.
What to watch next: The efficacy bar is set high, so watch the multiple-dose data (still ongoing), the fuller results Arrowhead has reserved for a future medical meeting, and how the LDL-plus-triglyceride 'dimer' approach stacks up against single-target RNAi rivals. A stock that sold off on good news can re-rate on the more complete dataset — or stay volatile if expectations remain elevated.
Frequently asked questions
Why did Arrowhead Pharmaceuticals, Inc. (ARWR) stock fall on Sep 15, 2026?
Arrowhead Pharmaceuticals fell 12.40% to $70.67 on Tuesday, September 15, 2026 — its worst day in over a year — even though its first-in-human data for ARO-DIMER-PA, released before the open, were positive. The Phase 1/2a single-dose interim results showed deep lipid reductions with no drug-related serious adverse events, but the stock had run hard into the readout and the disclosure was single-dose only, so the sharp drop read as sell-the-news/profit-taking rather than a reaction to disappointing data.
How much did ARWR stock fall on Sep 15, 2026?
ARWR fell 12.4% during the Sep 15, 2026 trading session.
What were the main drivers behind ARWR's move?
First-in-human ARO-DIMER-PA data (Phase 1/2a, single-dose interim); A sell-the-news reaction, not disappointing data; Worst single day in over a year.